Please try another search
Advanced Accelerator Applications SA develops, produces, and commercializes molecular nuclear, diagnostic, and therapeutic medicine products. It offers oxodotreotides; dotatate injections; edotreotide solutions; flurochol; and gluscan for oncology, cardiology, and neurology. It also provides LysaKare, a solution for reduction of kidney radiation exposure during peptide-receptor radionuclide therapy; DOPAVIEW, an aromatic amino acid that accumulates rapidly in target tissues; CARDIOGEN, closed system used to produce rubidium chloride for intravenous use; NEUROLITE, a radiopharmaceutical preparation of technetium bicisate injection; LUMARK, a radiopharmaceutical precursor; and LEUKOKIT, a medical device for the separation and labelling of autologous leukocytes. Additionally, it offers theragnostic platform, which is based on radiolabeling a targeting molecule for a receptor expressed on a tumor cell that helps in diagnosis, monitoring, and staging. The company was incorporated in 2002 and is based in Saint-Genis-Pouilly, France. Advanced Accelerator Applications SA operates as a subsidiary of Novartis AG.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review